Lexaria Bioscience Announces That It Has Received Partial 12-Week Body Weight Results From The Recently Completed Animal Study WEIGHT-A24-1
Lexaria Bioscience Announces That It Has Received Partial 12-Week Body Weight Results From The Recently Completed Animal Study WEIGHT-A24-1
DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing weight loss groups
DehydraTECH-liraglutide和選定的DehydraTECH-CBD配方是表現最佳的減重組
Accelerated rates of weight loss were experienced during the final 4 weeks of the study in all DehydraTECH groups
在所有DehydraTECH組的最後4周，體重減輕速度加快
KELOWNA, BC / ACCESSWIRE / October 22, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received partial 12-week (final) body weight results from the recently completed animal study WEIGHT-A24-1 (the "Study").
BC省KELOWNA / ACCESSWIRE / 2024年10月22日 / Lexaria Bioscience corp（納斯達克:LEXX）&（納斯達克:LEXXW）（"公司"或"Lexaria"），是一家全球創新的藥物輸送平台公司，宣佈從最近完成的動物研究WEIGHt-A24-1（"研究"）中收到了部分12周（最終）體重結果。
譯文內容由第三人軟體翻譯。